Webinar: PrEP in 2019: News You Can Use
![20190911 – PrEP in 2019 News You Can Use Title Slide](https://www.seaetc.com/wp-content/uploads/2019/09/20190911-PrEP-in-2019-News-You-Can-Use-Title-Slide.jpg)
Facilitated by Christopher B. Hurt, MD
Assistant Professor of Medicine
University of North Carolina at Chapel Hill
September 11, 2019
Objectives
- Summarize some of the new data on PrEP from scientific conferences in 2019
- Identify the differences and similarities of FTC/TDF and FTC/TAF for PrEP
- Discuss how HIV prevention advocates have approached issues related to pricing and availability of PrEP in the US
- Explain the controversy over patents for PrEP and the meaning of the Truvada lawsuits
- Describe the potential impact of the US Preventive Services Task Force’s new recommendation for PrEP
Presentation
Slides
![20190911 – PrEP in 2019 News You Can Use Title Slide](https://www.seaetc.com/wp-content/uploads/2019/09/20190911-PrEP-in-2019-News-You-Can-Use-Title-Slide.jpg)
Facilitated by Christopher B. Hurt, MD
Assistant Professor of Medicine
University of North Carolina at Chapel Hill
September 11, 2019
Objectives
- Summarize some of the new data on PrEP from scientific conferences in 2019
- Identify the differences and similarities of FTC/TDF and FTC/TAF for PrEP
- Discuss how HIV prevention advocates have approached issues related to pricing and availability of PrEP in the US
- Explain the controversy over patents for PrEP and the meaning of the Truvada lawsuits
- Describe the potential impact of the US Preventive Services Task Force’s new recommendation for PrEP
Presentation
Slides
![20190911 – PrEP in 2019 News You Can Use Title Slide](https://www.seaetc.com/wp-content/uploads/2019/09/20190911-PrEP-in-2019-News-You-Can-Use-Title-Slide.jpg)
Facilitated by Christopher B. Hurt, MD
Assistant Professor of Medicine
University of North Carolina at Chapel Hill
September 11, 2019
Objectives
- Summarize some of the new data on PrEP from scientific conferences in 2019
- Identify the differences and similarities of FTC/TDF and FTC/TAF for PrEP
- Discuss how HIV prevention advocates have approached issues related to pricing and availability of PrEP in the US
- Explain the controversy over patents for PrEP and the meaning of the Truvada lawsuits
- Describe the potential impact of the US Preventive Services Task Force’s new recommendation for PrEP